Technology
Health
Biotechnology

Biocept

$1.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (19.42%) Today
-$0.04 (-3.25%) After Hours

Why Robinhood?

You can buy or sell Biocept and other stocks, options, ETFs, and crypto commission-free!

About

Biocept, Inc. Common Stock, also called Biocept, is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. Read More It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Employees
95
Headquarters
San Diego, California
Founded
1997
Market Cap
4.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
986.37K
High Today
$1.35
Low Today
$1.10
Open Price
$1.11
Volume
11.79M
52 Week High
$12.15
52 Week Low
$0.658

Collections

Technology
Health
Biotechnology
Medical
Advertising and Marketing
Biopharmaceutical
Business Services
Pharmaceutical

News

PR Newswire9h

Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment

SAN DIEGO, March 26, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will begin commercializing its recently expanded pathology partnership platform, EmpowerTC, to urology and uropathology practices. Biocept has expanded the capability of EmpowerTC to perform biomarker tests that can aid physicians and patho...

814
PR NewswireMar 18

Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device

SAN DIEGO, March 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Japanese Patent No. 6463668 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers a microchannel device and antibodies for the capture of rare cells of interest, including CTCs that are shed i...

463
PR NewswireMar 13

Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services

SAN DIEGO, March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has expanded its pathology partnership platform, EmpowerTCTM, to now offer local pathologists the ability to analyze prognostic and predictive markers on CTCs from a liquid biopsy using immunocytochemistry (ICC) methods. This new offering, ...

1,961

Earnings

-$3.30
-$2.23
-$1.16
-$0.09
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$1.58 per share
Actual
Available Mar 28, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.